Cited by 63Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsCerebrospinal fluid and hydrocephalus

Combined Effects of Alzheimer Risk Variants in the CLU and ApoE Genes on Ventricular Expansion Patterns in the Elderly

Open access
Roussotte, Florence F., Gutman, Boris A., Madsen, Sarah K., Colby, John B., Thompson, Paul M., for the Alzheimer's Disease Neuroimaging Initiative·2014·The Journal of Neuroscience

Abstract

The C allele at the rs11136000 locus in the clusterin ( CLU ) gene is the third strongest known genetic risk factor for late-onset Alzheimer's disease (LOAD). A recent genome-wide association study of LOAD found the strongest evidence of association with CLU at rs1532278, in high linkage disequilibrium with rs11136000. Brain structure and function are related to the CLU risk alleles, not just in LOAD patients but also in healthy young adults. We tracked the volume of the lateral ventricles across baseline, 1-year, and 2-year follow-up scans in a large sample of elderly human participants ( N = 736 at baseline), from the Alzheimer's Disease Neuroimaging Initiative, to determine whether these CLU risk variants predicted longitudinal ventricular expansion. The rs11136000 major C allele—previously linked with reduced CLU expression and with increased risk for dementia—predicted faster expansion, independently of dementia status or ApoE genotype. Further analyses revealed that the CLU and ApoE risk variants had combined effects on both volumetric expansion and lateral ventricle surface morphology. The rs1532278 locus strongly resembles a regulatory element. Its association with ventricular expansion was slightly stronger than that of rs11136000 in our analyses, suggesting that it may be closer to a functional variant. Clusterin affects inflammation, immune responses, and amyloid clearance, which in turn may result in neurodegeneration. Pharmaceutical agents such as valproate, which counteract the effects of genetically determined reduced clusterin expression, may help to achieve neuroprotection and contribute to the prevention of dementia, especially in carriers of these CLU risk variants.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1523/jneurosci.5236-13.2014

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • SIAH3 has been associated through another GWAS with rate of ventricular enlargement in the ADNI cohort, and this association has also been observed separately with variants near CLU.

    “In addition, SIAH3 has been associated through another GWAS to rate of ventricular enlargement in the ADNI cohort [42], an association that has also been separately observed with variants near CLU [43].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 58 · Cited by 63

Authors
Roussotte, F. F., Gutman, B. A., Madsen, S. K., Colby, J. B., Thompson, P. M., & Initiative, F. T. A. D. N.
Affiliations
University of Southern California (US)
Venue
The Journal of Neuroscience
Published
2014-05-07
Volume
34
Issue
19
Pages
6537-6545
ISSN
  • 0270-6474 (ISSN-L)
  • 1529-2401
OpenAlex
W2102641393
Cited by
63
References
58
Citations by year
2026: 3 · 2025: 2 · 2024: 2 · 2023: 10 · 2022: 4 · 2021: 7 · 2020: 8 · 2019: 4 · 2018: 5 · 2017: 7 · 2016: 7 · 2015: 4
FWCI
4.54
Type
journal article
Language
en
Open access
Locations
  • Journal of Neuroscience (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Foundation for the National Institutes of Health (P30AG010129, K01 AG030514, U01AG024904, Grant U01 AG024904, AG024904)
  • Alzheimer's Association (AG010129, U01 AG024904)
  • A.P. Giannini Foundation
  • Bristol-Myers Squibb (U01 AG024904, AG024904)
  • Eli Lilly and Company (U01 AG024904, AG024904)
  • Pfizer (AG024904, U01 AG024904)
  • Biogen (U01 AG024904, AG024904)
  • University of Southern California (U01 AG024904)
  • F. Hoffmann-La Roche (AG024904, U01 AG024904)
  • Medpace (U01 AG024904)
  • Meso Scale Diagnostics (U01 AG024904, AG024904)
  • Synarc (U01 AG024904, P30 AG010129, K01 AG030514)
  • Alzheimer's Disease Neuroimaging Initiative (U01AG024904, AG024904, R01 AG040060, P30 AG010129, K01 AG030514)
  • BioClinica (U01 AG024904, AG024904)
  • Novartis Pharmaceuticals Corporation (U01 AG024904, AG024904)
  • Giannini Foundation of Agricultural Economics
  • Northern California Institute for Research and Education (U01 AG024904, K01 AG030514, P30 AG010129)
  • Eisai (U01 AG024904, AG024904)
  • Servier (AG024904, U01 AG024904)
  • IXICO (AG024904, U01 AG024904)
  • National Institutes of Health (3u01ag024904-10s2, U01-AG024904, Grant U01 AG024904, P30 AG010129 and K01 AG030514, AG010129, AG024904)
  • Genentech (AG024904, U01 AG024904)
  • University of California, San Diego
  • Canadian Institutes of Health Research (U01 AG024904, K01 AG030514, P30 AG010129)
  • National Institute on Aging (U01-AG-024904, P30AG010129, AG 024904, K01AG030514, AG010129, R01AG040060, U24AG021886)
  • National Institute of Mental Health (R01MH097268)
  • National Institute of Biomedical Imaging and Bioengineering (U01 AG024904, P41EB015922, AG024904)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Cerebrospinal fluid and hydrocephalus
Keywords
Alzheimer's disease, clusterin, CLU gene, apolipoprotein E, ventricular volume, genetic risk variants, longitudinal neuroimaging, older adults, valproic acid, neuroprotection, dementia prevention, amyloid clearance, neuroinflammation
MeSH terms
Aged, Aging, Alleles, Alzheimer Disease, Apolipoproteins E, Brain Mapping, DNA, Female, Genotype, Humans, Image Processing, Computer-Assisted, Magnetic Resonance Imaging, Male, Regression Analysis, Risk, Lateral Ventricles, Clusterin, Genome-Wide Association Study, Real-Time Polymerase Chain Reaction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review